Skip to main content
SpringerLink
Log in

Management of deepCandida infection in surgical and intensive care unit patients

  • Expert Panel
  • Published:
Intensive Care Medicine Aims and scope Submit manuscript

Abstract

DeepCandida infections are increasing in incidence, especially in non-neutropenic, intensive care patients including neonates. The attributable mortality of candidaemia andcandida peritonitis is 37–38% with a 57% overall mortality. The BSAC set up a working party to develop recommendations for management in the absence of controlled trials. These recommendations focus on the role of the microbiology laboratory, management strategies, the respective roles of amphotericin B, flucytosine and fluconazole and long-term maintenance therapy. The indications for initiation of therapy are given special consideration.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Komshian SV, Uwaydah AK, Sobel JD, Crane LR (1989) Fungemia caused byCandida species andTorulopsis glabrata in the hospitalized patient: frequency, characteristics, and evaluation of factors influencing outcome. Rev Infect Dis 11:379–390

    Google Scholar 

  2. Wenzel RP, Pfaller MA (1991)Candida species: emerging hospital bllodstream pathogens. Infect Control Hosp Epidemiol 12:523–524

    Google Scholar 

  3. Fraser VJ, Jones M, Dunkel J, Storfer S, Medoff G, Dunagan WC (1992) Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality. Clin Infect Dis 15:414–421

    Google Scholar 

  4. Denning DW (1991) Epidemiology and pathogenesis of systemic fungal infection in the immunocompromised host. J Antimicrob Chemother 28 [Suppl B]:1–16

    Google Scholar 

  5. Edwards JE (1991) Invasivecandida infections. Evolution of a fungal pathogen. N Engl J Med 324:1059–1062

    Google Scholar 

  6. Wey SB, Mori M, Pfaller MA, Woolson RF, Wenzel RP (1988) Hospital-acquired candidemia. The attributable mortality and excess length of stay. Arch Intern Med 148:2642–2645

    Google Scholar 

  7. Johnson D, Thompson T, Green T, Ferrieri P (1984) Systemic candidiasis in very low birth weight infants (<1500 g). Pediatrics 73:138–143

    Google Scholar 

  8. Baley J, Kleigman R, Fanaroff A (1984) Disseminated fungal infections in very low birth weight infants: Clinical manifestations and epidemiology. Pediatrics 73:144–152

    Google Scholar 

  9. Sanchez P, Siegel J, Fishbein J (1991)Candida endocarditis: successful medical management in three preterm infants and review of the literature. Pediatr Infect Dis J 10:239–243

    Google Scholar 

  10. British Society for Antimicrobial Chemotherapy Working Party (1987) Diagnosis and management of peritonitis in continuous ambulatory peritoneal dialysis. Lancet I:845–849

    Google Scholar 

  11. Leen CLS, Brettle RP (1991) Fungal infections in drug abusers. J Antimicrobial Chemother 28 [Suppl A]:83–96

    Google Scholar 

  12. British Society for Antimicrobial Chemotherapy Working Party on Fungal Infection (1992) Treatment of fungal infections in AIDS. Lancet 340:648–651

    Google Scholar 

  13. Dupont B (1991) Clinical manifestations and management of candidosis in the compromised patient. In: Warnock DW, Richardson MD (eds) Fungal infection in the compromised patient. Wiley, Chichester, pp 55–83

    Google Scholar 

  14. EPIC Study Group (1992) The EPIC study — preliminary results. HOST 9:12–13

    Google Scholar 

  15. Calandra T, Bille J, Schneider R, Mosimann F, Francioli P (1989) Clinical significance ofCandida isolated from peritoneum in surgical patients. Lancet II:1437–1440

    Google Scholar 

  16. Bayer AS, Blumenkrantz MJ, Montgomerie JZ, Galpin JE, Coburn JW, Guze LB (1976)Candida peritonitis: report of 22 cases and review of the English literature. Am J Med 61:832–840

    Google Scholar 

  17. British Society for Antimicrobial Chemotherapy Working Party on Fungal Infection (1991) Laboratory monitoring of antifungal chemotherapy. Lancet 357:1577–1580

    Google Scholar 

  18. Powderly WG, Kobayashi GS, Herzig GP, Medoff G (1988) Amphotericin B-resistant yeast infection in severely immunocompromised patients. Am J Med 84:826–832

    Google Scholar 

  19. O'Day DM, Ray WA, Robinson RD, Head WS, Williams TE (1991) Differences in response in vivo to amphotericin B amongCandida albicans strains. Invest Ophthalmol Vis Sci 32:1569–1572

    Google Scholar 

  20. Warnock DW, Burke J, Cope NJ, Johnson EM, von Fraunhofer NA, Williams EW (1988) Fluconazole resistance inCandida glabrata. Lancet II:1310

    Google Scholar 

  21. Vanden Bossche H, Marichal P, Odds FC, Le Jeune L, Coene M-C (1992) Characterization of an azole resistantCandida glabrata isolate. Antimicrob Agents Chemother 36:2602–2610

    Google Scholar 

  22. Seidenfeld SM, Cooper BH, Smith JW, Luby JP, Mackowiak PA (1983) Amphotericin B tolerance: a characteristic ofCandida parapsilosis not shared by otherCandida species. J Infect Dis 147:116–119

    Google Scholar 

  23. Wingard JR, Merz WG, Rinaldi MG, Johnson TR, Karp JE, Saral R (1991) Increase inCandida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med 325:1274–1277

    Google Scholar 

  24. Pappagianis D, Collins MS, Hector R, Remington J (1979) Development of resistance to amphotericin B inCandida lusitaniae infecting in human. Antimicrob Agents Chemother 16:123–126

    Google Scholar 

  25. Blinkhorn RJ, Adelstein D, Spagnuolo PJ (1989) Emergence of a new opportunistic pathogen,Candida lusitaniae. J Clin Microbiol 27:236–240

    Google Scholar 

  26. British Society for Antimicrobial Chemotherapy Working Party on Fungal Infection (1993) Antifungal prophylaxis in leukaemia and transplantation. J Antimicrob Chemother 32:5–21

    Google Scholar 

  27. Rubin RH (1991) Preemptive therapy in immuncompromised hosts. N Engl J Med 324:1057–1058

    Google Scholar 

  28. Schmidt GM, Horak DA, Niland JC et al (1991) A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogenic bone marrow transplants. N Engl J Med 324:1005–1011

    Google Scholar 

  29. Brajtburg J, Powderly WG, Kobayashi GS, Medoff G (1990) Amphotericin B: delivery systems. Antimicrob Agents Chemother 34:381–384

    Google Scholar 

  30. Clark JM, Whitney RR, Olsen SJ, George RJ, Swerdel MR, Kunselman L, Bonner DP (1991) Amphotericin B lipid complex therapy of experimental fungal infections in mice. Antimicrob Agents Chemother 35:615–621

    Google Scholar 

  31. Clemons KV, Stevens DA (1992) Efficacies of amphotericin B lipid complex (ABLC) and conventional amphotericin B against murine coccidioidomycosis. J Antimicrob Chemother 30:353–363

    Google Scholar 

  32. Van't Wout JW, Mattie H, Van Furth R (1988) A prospective study of the efficacy of fluconazole (UK-49,858) against deep-seated fungal infections. J Antimicrob Chemother 21:665–672

    Google Scholar 

  33. Ikemoto H (1989) A clinical study of fluconazole in the treatment of deep mycoses. Diagn Microbiol Infect Dis 12:S329-S247

    Google Scholar 

  34. Nolla-Salas J, León C, Torres-Rodríguez JM, Martín E, Sitges-Serra A (1992) Treatment of candidemia in critically ill surgical patients with intravenous fluconazole. Clin Infect Dis 14:952–954

    Google Scholar 

  35. Rex JH, Bennett JE, Sugar AM et al (1993) Fluconazole (FLU) vs. Amphotericin B (AMB) for treatment of candidemia: results of a randomized, multicenter trial. 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy, October 17–20, 1993. American Society for Microbiology: Abstract 805

  36. Graninger W, Presteril E, Schneeweiss B, Teleky B, Georgopoulos A (1992) Treatment ofCandida albicans fungaemia with fluconazole. J Infect 26:133–146

    Google Scholar 

  37. Kujath P, Lerch K (1989) New antimicrobial agents under clinical investigation. Secondary mycosis in surgery: treatment with fluconazole. Infection 13:111–117

    Google Scholar 

  38. Eppes SC, Troutman JL, Gutman LT (1989) Outcome of treatment of candidemia in childen whose central catheters were removed or retained. Pediatr Infect Dis J 8:99–104

    Google Scholar 

  39. Dato VM, Dajani AS (1990) Candidemia in children with central venous catheters: role of catheter removal and amphotericin B therapy. Pediatr Infect Dis J 9:309–314

    Google Scholar 

  40. Sanford JP (1993) The enigma of candiduria: Evolution of bladder irrigation with amphotericin B for management — from anecdote to dogma and a lesson from Machiavelli. Clin Infect Dis 16:145–147

    Google Scholar 

  41. Walsh TJ, Hutchins GM, Bulkley BH, Mendelsohn G (1980) Fungal infections of the heart: analysis of 51 autopsy cases. Am J Cardiol 45:357–366

    Google Scholar 

  42. Rubinstein E, Noriega ER, Simberkoff MS, Holzman R, Rahal JJ (1975) Fungal endocarditis: analysis of 24 cases and review of the literature. Medicine 54:331–344

    Google Scholar 

  43. Weems JJ (1992)Candida parapsilosis: Epidemiology, pathogenicity, clinical manifestations and antimicrobial susceptibility. Clin Infect Dis 14:756–766

    Google Scholar 

  44. Rudd RM, Hill PR, Kopelman P, Parker DJ (1980) Fungal endocarditis after homograft valve replacement: difficulties in diagnosis and treatment. Thorax 35:686–689

    Google Scholar 

  45. Galgiani JN, Stevens DA (1977) Fungal endocarditis: need for guidelines in evaluating therapy. J Thorac Cardiovasc Surg 73:293–296

    Google Scholar 

  46. Walsh TJ, Bustamente CI, Vlahov D, Standiford HC (1986) Candidal suppurative peripheral thrombophlebitis: recognition, prevention, and management. Infect Control 7:16–22

    Google Scholar 

  47. Lipton SA, Hickey WF, Morris JH, Losclzo J (1984) Candidal infection in the central nervous system. Am J Med 76:101–108

    Google Scholar 

  48. Brooks RG (1989) Prospective study ofCandida endophthalmitis in hospitalized patients with candidemia. Arch Intern Med 149:2226–2228

    Google Scholar 

  49. Schmid S, Martenet AC, Oelz O (1991)Candida endophthalmitis: Clinical presentation, treatment and outcome in 23 patients. Infection 19:21–24

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Infectious Diseases and Tropical Medicine (Monsall Unit), North Manchester General Hospital, Delaunay's Road, M8 6RB, Manchester, UK

    D. W. Denning

Authors
  1. D. W. Denning
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

British Society for Antimicrobial Chemotherapy Working Party

Additional information

Participants: J. Cohen, Chairman, Royal Postgraduate Medical School, London; D. W. Denning, Rapporteur, North Manchester General and Hope Hospitals and University of Manchester; E. G. V. Evans, University of Leeds; R. J. Hay, United Medical and Dental Schools of Guy's and St. Thomas' Hospital, London; D. W. R. Mackenzie, London School of Hygiene and Tropical Medicine,; A.G. Prentice, Derriford Hospital, Plymouth; T.R.F. Rogers, Royal Postgraduate Medical School, London; D.C.E. Speller, University of Bristol, Bristol; D.W. Warnock, Public Health Laboratory, Bristol; R.E. Warren, Royal Shrewsbury Hospital, Shrewsbury

Rights and permissions

Reprints and permissions

About this article

Cite this article

British Society for Antimicrobial Chemotherapy Working Party., Denning, D.W. Management of deepCandida infection in surgical and intensive care unit patients. Intensive Care Med 20, 522–528 (1994). https://doi.org/10.1007/BF01711909

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01711909

Key words

Search

Navigation